Analyst Price Target is $476.00
▲ +26.19% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Bio-Techne in the last 3 months. The average price target is $476.00, with a high forecast of $548.00 and a low forecast of $400.00. The average price target represents a 26.19% upside from the last price of $377.22.
Current Consensus is
The current consensus among 8 polled investment analysts is to buy stock in Bio-Techne. This Buy consensus rating has held steady for over two years.
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics &Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics &Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate(IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The co